Sanofi / Regeneron Clinical Trial Pipeline — 180 Active Studies

Phases, active trials: Phase 1: 9, Phase 2: 57, Phase 3: 56, Other: 58

Sanofi and Regeneron operate an extensive co-development partnership spanning immunology, oncology, and rare disease. Dupixent (dupilumab), the IL-4Rα-blocking antibody, is the fastest-growing biologic in history — and Sanofi continues expanding its label into new type-2 inflammatory conditions (COPD, prurigo nodularis, alopecia areata). Their shared oncology pipeline includes cemiplimab (Libtayo), the PD-1 inhibitor with approvals in skin cancers and NSCLC, plus a broad REGN antibody program in hematology and solid tumors. Sanofi's rare disease heritage (Gaucher, Pompe, Fabry) continues with next-generation enzyme replacement therapies and gene therapies.

• Type-2 inflammation / allergy (IL-4Rα, IL-33, TSLP)
• Oncology (PD-1, bispecifics, hematology)
• Rare / metabolic disease (lysosomal storage, hemophilia)
• Neurology
• Vaccines (Beyfortus RSV)

• Dupixent (dupilumab) — IL-4Rα, atopic dermatitis/asthma/COPD
• Libtayo (cemiplimab) — PD-1, skin cancers/NSCLC
• Sarclisa (isatuximab) — anti-CD38, multiple myeloma
• Zynquista (sotagliflozin) — SGLT1/2, T1D/heart failure
• REGN5458 — BCMAxCD3 bispecific, myeloma
• Fitusiran — RNAi-based hemophilia therapy

Dupixent's label expansion program generates consistent new trial registrations across type-2 inflammatory conditions. Any company developing IL-4, IL-13, IL-33, or TSLP-targeted therapies needs to monitor Sanofi/Regeneron's trial activity closely.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Sanofi / Regeneron's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: Sanofi / Regeneron may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.